By Fineline Cube 
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to its B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248). The designation is for the treatment of patients with recurrent/refractory mantle cell lymphoma (R/R MCL) who have developed resistance to BTK inhibitors.
Mechanism of Action
Mesutoclax is a novel, orally bioavailable BCL2-selective inhibitor. It is designed to treat hematologic malignancies either as a monotherapy or in combination with other therapies. By selectively inhibiting BCL2, the drug restores the mechanism of programmed cell death, thereby achieving an anti-tumor effect. Preclinical data have indicated a favorable efficacy and safety profile for mesutoclax.-Fineline Info & Tech